Drug Policy Down Under: Australia's Pharmaceutical Benefits Scheme
نویسنده
چکیده
Australia has had a government subsidized universal system of pharmaceutical provision for 50 years. The Pharmaceutical Benefits Scheme (PBS) consumes around 14 percent of total government health care expenditures and has grown substantially in both range of drugs covered, and expenditure since it was first introduced in 1950. It incorporates patient copayments (with differentials for the general population compared with concessional beneficiaries). Prior to listing a drug on the PBS it is subject to a rigorous cost-effectiveness analysis.
منابع مشابه
Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
متن کامل
Reshaping Australian drug policy: the dilemmas of generic medicines policy
With this edition, Australia New Zealand Health Policy publishes four articles on the theme of Australian and international generic medicines market dynamics and policy dilemmas. Changes soon to be introduced to pricing arrangements under Australia's Pharmaceutical Benefits Scheme (PBS) make this focus particularly topical. Beecroft presents a community pharmacy perspective on these issues. Fau...
متن کاملAre Australia's drugs too cheap for our own good?
The Pharmaceutical Benefits Advisory Committee (PBAC) plays an important role in controlling the drugs that are available at subsidised prices under the Pharmaceutical Benefits Scheme (PBS). In brief, the Committee provides advice on whether a new drug is sufficiently cost-effective to merit its being added to the PBS. Listing is important to the drug manufacturers, because it has a beneficial ...
متن کاملHow are pharmaceutical patent term extensions justified? Australia's evolving scheme.
This article examines the evolving patent term extension schemes under the Patents Act 1903 (Cth), the Patents Act 1952 (Cth) and the Patents Act 1990 (Cth). The analysis traces the change from "inadequate remuneration" to a scheme directed specifically at certain pharmaceuticals. An examination of the policy justification shows there are legitimate questions about the desirability of any exten...
متن کاملDistributional impact of higher patient contributions to Australia's Pharmaceutical Benefits Scheme.
This paper uses NATSEM's Pharmaceutical Benefits Model to analyse the effects of a hypothetical 25 per cent rise in patient contributions to prescribed medicines under Australia's Pharmaceutical Benefits Scheme (PBS). The model, based on microsimulation techniques, is able to provide a much broader range of outcomes information, at a much greater level of detail, than is possible with tradition...
متن کامل